Annual CFF
-$2.46 M
+$30.11 M+92.44%
31 December 2023
Summary:
ProQR Therapeutics NV annual cash flow from financing activities is currently -$2.46 million, with the most recent change of +$30.11 million (+92.44%) on 31 December 2023. During the last 3 years, it has fallen by -$19.02 million (-114.87%). PRQR annual CFF is now -101.52% below its all-time high of $161.90 million, reached on 31 December 2021.PRQR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$514.40 K
-$214.70 K-71.64%
01 September 2024
Summary:
ProQR Therapeutics NV quarterly cash flow from financing activities is currently -$514.40 thousand, with the most recent change of -$214.70 thousand (-71.64%) on 01 September 2024. Over the past year, it has dropped by -$209.90 thousand (-68.93%). PRQR quarterly CFF is now -100.49% below its all-time high of $104.52 million, reached on 30 September 2014.PRQR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$2.44 M
-$209.90 K-9.39%
01 September 2024
Summary:
ProQR Therapeutics NV TTM cash flow from financing activities is currently -$2.44 million, with the most recent change of -$209.90 thousand (-9.39%) on 01 September 2024. Over the past year, it has dropped by -$13.56 million (-121.98%). PRQR TTM CFF is now -101.51% below its all-time high of $161.90 million, reached on 31 December 2021.PRQR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PRQR Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +92.4% | -68.9% | -122.0% |
| 3 y3 years | -114.9% | -102.0% | -101.9% |
| 5 y5 years | -102.4% | -59.0% | -191.1% |
PRQR Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -101.5% | +92.4% | -101.6% | +98.8% | -101.5% | +92.5% |
| 5 y | 5 years | -101.5% | +92.4% | -100.5% | +98.8% | -101.5% | +92.5% |
| alltime | all time | -101.5% | +92.4% | -100.5% | +98.8% | -101.5% | +92.5% |
ProQR Therapeutics NV Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$514.40 K(+71.6%) | -$2.44 M(+9.4%) |
| June 2024 | - | -$299.70 K(-34.1%) | -$2.23 M(-15.4%) |
| Mar 2024 | - | -$455.10 K(-61.3%) | -$2.64 M(+7.2%) |
| Dec 2023 | -$2.46 M(-92.4%) | -$1.17 M(+285.8%) | -$2.46 M(-122.2%) |
| Sept 2023 | - | -$304.50 K(-56.8%) | $11.12 M(-134.1%) |
| June 2023 | - | -$705.40 K(+153.6%) | -$32.60 M(+1.1%) |
| Mar 2023 | - | -$278.20 K(-102.2%) | -$32.25 M(-1.0%) |
| Dec 2022 | -$32.58 M(-120.1%) | $12.41 M(-128.2%) | -$32.58 M(+157.5%) |
| Sept 2022 | - | -$44.02 M(>+9900.0%) | -$12.65 M(-122.2%) |
| June 2022 | - | -$349.30 K(-42.7%) | $56.90 M(-63.9%) |
| Mar 2022 | - | -$609.30 K(-101.9%) | $157.69 M(-2.6%) |
| Dec 2021 | $161.90 M(+877.7%) | $32.33 M(+26.7%) | $161.90 M(+25.1%) |
| Sept 2021 | - | $25.53 M(-74.6%) | $129.40 M(+8.3%) |
| June 2021 | - | $100.44 M(+2692.4%) | $119.44 M(+511.2%) |
| Mar 2021 | - | $3.60 M(-2260.4%) | $19.54 M(+18.0%) |
| Dec 2020 | $16.56 M(-70.5%) | -$166.50 K(-101.1%) | $16.56 M(-77.3%) |
| Sept 2020 | - | $15.57 M(+2780.3%) | $72.93 M(+27.9%) |
| June 2020 | - | $540.60 K(-12.1%) | $57.03 M(+1.4%) |
| Mar 2020 | - | $614.70 K(-98.9%) | $56.27 M(+0.1%) |
| Dec 2019 | $56.20 M | $56.20 M(<-9900.0%) | $56.20 M(+1994.3%) |
| Sept 2019 | - | -$323.50 K(+44.5%) | $2.68 M(-97.4%) |
| June 2019 | - | -$223.90 K(-141.3%) | $101.88 M(-0.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | $541.80 K(-79.9%) | $102.26 M(+0.2%) |
| Dec 2018 | $102.09 M(+238.4%) | $2.69 M(-97.3%) | $102.09 M(-14.1%) |
| Sept 2018 | - | $98.88 M(>+9900.0%) | $118.86 M(+339.6%) |
| June 2018 | - | $154.40 K(-58.2%) | $27.04 M(-4.3%) |
| Mar 2018 | - | $369.80 K(-98.1%) | $28.25 M(-6.4%) |
| Dec 2017 | $30.17 M(+7536.0%) | $19.46 M(+175.7%) | $30.17 M(+176.6%) |
| Sept 2017 | - | $7.06 M(+416.6%) | $10.91 M(+183.3%) |
| June 2017 | - | $1.37 M(-40.4%) | $3.85 M(+55.0%) |
| Mar 2017 | - | $2.29 M(+1080.5%) | $2.48 M(+528.6%) |
| Dec 2016 | $395.10 K(-78.0%) | $194.20 K(-7868.0%) | $395.10 K(-36.2%) |
| Sept 2016 | - | -$2500.00(+257.1%) | $619.40 K(-1.8%) |
| June 2016 | - | -$700.00(-100.3%) | $630.80 K(-68.6%) |
| Mar 2016 | - | $204.10 K(-51.2%) | $2.01 M(+11.8%) |
| Dec 2015 | $1.80 M(-98.9%) | $418.50 K(+4602.2%) | $1.80 M(-15.2%) |
| Sept 2015 | - | $8900.00(-99.4%) | $2.12 M(-98.0%) |
| June 2015 | - | $1.38 M(<-9900.0%) | $106.63 M(-33.1%) |
| Mar 2015 | - | -$7900.00(-101.1%) | $159.44 M(+0.0%) |
| Dec 2014 | $159.43 M(+1790.7%) | $740.40 K(-99.3%) | $159.43 M(+0.5%) |
| Sept 2014 | - | $104.52 M(+92.9%) | $158.68 M(+193.0%) |
| June 2014 | - | $54.18 M(<-9900.0%) | $54.16 M(<-9900.0%) |
| Mar 2014 | - | -$20.50 K | -$20.50 K |
| Dec 2013 | $8.43 M | - | - |
FAQ
- What is ProQR Therapeutics NV annual cash flow from financing activities?
- What is the all time high annual CFF for ProQR Therapeutics NV?
- What is ProQR Therapeutics NV annual CFF year-on-year change?
- What is ProQR Therapeutics NV quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for ProQR Therapeutics NV?
- What is ProQR Therapeutics NV quarterly CFF year-on-year change?
- What is ProQR Therapeutics NV TTM cash flow from financing activities?
- What is the all time high TTM CFF for ProQR Therapeutics NV?
- What is ProQR Therapeutics NV TTM CFF year-on-year change?
What is ProQR Therapeutics NV annual cash flow from financing activities?
The current annual CFF of PRQR is -$2.46 M
What is the all time high annual CFF for ProQR Therapeutics NV?
ProQR Therapeutics NV all-time high annual cash flow from financing activities is $161.90 M
What is ProQR Therapeutics NV annual CFF year-on-year change?
Over the past year, PRQR annual cash flow from financing activities has changed by +$30.11 M (+92.44%)
What is ProQR Therapeutics NV quarterly cash flow from financing activities?
The current quarterly CFF of PRQR is -$514.40 K
What is the all time high quarterly CFF for ProQR Therapeutics NV?
ProQR Therapeutics NV all-time high quarterly cash flow from financing activities is $104.52 M
What is ProQR Therapeutics NV quarterly CFF year-on-year change?
Over the past year, PRQR quarterly cash flow from financing activities has changed by -$209.90 K (-68.93%)
What is ProQR Therapeutics NV TTM cash flow from financing activities?
The current TTM CFF of PRQR is -$2.44 M
What is the all time high TTM CFF for ProQR Therapeutics NV?
ProQR Therapeutics NV all-time high TTM cash flow from financing activities is $161.90 M
What is ProQR Therapeutics NV TTM CFF year-on-year change?
Over the past year, PRQR TTM cash flow from financing activities has changed by -$13.56 M (-121.98%)